CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 110 enrolled
Drug / intervention
Ketorolac Injection 15 mg +1 moredrug
Likely dose
Ketorolac Injection 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04763876
NCT04763876Phase 4Completed
CompareCT.gov

Comparison of Intramuscular Ketorolac at Two Single-Dose Regimens for Treatment of Acute Musculoskeletal Pain in a Military Emergency Department: A Randomized Controlled Non-Inferiority Trial

William Beaumont Army Medical Center·interventional·Posted Feb 21, 2021·Updated Oct 15, 2025

In Brief

A Phase 4 clinical trial evaluating Ketorolac Injection 15 mg and Ketorolac Injection 60 mg for Musculoskeletal Pain and 2 related conditions. Completed, enrolled 110 participants across 1 site.

Detailed Summary

The purpose of this study was to evaluate a single 15 mg intramuscular (IM) dose of ketorolac for analgesic non-inferiority versus a single 60 mg IM dose for the treatment of acute MSK pain in a military emergency department (ED) that services Department of Defense (DoD), Department of Veteran Affairs (VA), and foreign military beneficiaries

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMusculoskeletal Pain, Analgesia, Adverse Event
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedFeb 21, 2021
Enrollment StartJun 27, 2020
Primary CompletionNov 9, 2020
Study CompletionFeb 4, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.4 years ago

Interventions

Ketorolac Injection 15 mgdrug

A single dose of 15 mg ketorolac administered intramuscularly.

Ketorolac Injection 60 mgdrug

A single dose of 60 mg ketorolac administered intramuscularly.